1
|
Soni A, Jadhav GK, Manocha S, Chauhan S, Goswami B, Verma M. Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer. Rep Pract Oncol Radiother 2022; 27:1001-1009. [PMID: 36632300 PMCID: PMC9826658 DOI: 10.5603/rpor.a2022.0116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Accepted: 10/28/2022] [Indexed: 12/12/2022] Open
Abstract
Background The purpose of this study was to comparatively evaluate an efficacy and toxicity profile of hypofractionated radiotherapy (67.5 Gy in 25 fractions) to conventionally fractionated radiotherapy (78 Gy in 39 fractions) in prostate cancer patients with intermediate and high-risk disease. Materials and methods From January 2015 to December 2018, 168 patients were randomized to hypofractionated radiation treatment and conventional fractionated radiation treatment schedules of volumetric modulated arc therapy (VMAT) to the prostate and seminal vesicles. All the patients also received androgen deprivation therapy (ADT) and radiation therapy started after ADT. Results The median (range) follow-up was 51 (31-63) and 53 (33-64) months in the hypofractionated and conventionally fractionated regimes, respectively. The 3-year biochemical no evidence of disease (bNED) rates were 86.9% and 73.8% in the hypofractionated and conventionally fractionated groups, respectively (p = 0.032, significant). The 3-year bNED rates in patients at a high risk [i.e., pretreatment prostate-specific antigen (PSA) > 20 ng/mL, Gleason score ≥ 8, or T ≥ 2 c], were 87.9% and 73.5% (p = 0.007, significant) in the hypofractionated and conventionally fractionated radiotherapy groups, respectively. No statistically significant difference was found for late toxicity between the two groups, with 3-year grade 2 gastrointestinal toxicity rates of 19% and 16.7% and 3-year grade 2 genitourinary toxicity rates of 15.5% and 11.9% in the hypofractionated and conventionally fractionated radiotherapy groups, respectively. Conclusion Hypofractionated schedule is superior to the conventional fractionation schedule of radiation treatment in terms of bNED in intermediate and high grade prostate cancer patients. Also, the late toxicity is found to be equivalent between the two treatment groups.
Collapse
Affiliation(s)
- Abhishek Soni
- Department of Radiation Oncology, PT Bhagwat Dayal Sharma, Rohtak, India
| | - Ganesh K Jadhav
- Department of Radiation Oncology, Indraprastha Apollo Hospital, New Delhi, India
| | - Sapna Manocha
- Department of Radiation Oncology, Indraprastha Apollo Hospital, New Delhi, India
| | - Sunil Chauhan
- Department of Radiation Oncology, Indraprastha Apollo Hospital, New Delhi, India
| | - Brijesh Goswami
- Department of Radiation Oncology, Indraprastha Apollo Hospital, New Delhi, India
| | - Monica Verma
- Department of Radiation Oncology, PT Bhagwat Dayal Sharma, Rohtak, India
| |
Collapse
|
2
|
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 2016; 17:464-474. [DOI: 10.1016/s1470-2045(15)00567-7] [Citation(s) in RCA: 169] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 11/30/2015] [Accepted: 12/02/2015] [Indexed: 11/19/2022]
|
3
|
Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 2015; 16:274-83. [PMID: 25656287 DOI: 10.1016/s1470-2045(14)70482-6] [Citation(s) in RCA: 127] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND In 2007, we began the randomised phase 3 multicentre HYPRO trial to investigate the effect of hypofractionated radiotherapy compared with conventionally fractionated radiotherapy on relapse-free survival in patients with prostate cancer. Here, we examine whether patients experience differences in acute gastrointestinal and genitourinary adverse effects. METHODS In this randomised non-inferiority phase 3 trial, done in seven radiotherapy centres in the Netherlands, we enrolled intermediate-risk or high-risk patients aged between 44 and 85 years with histologically confirmed stage T1b-T4 NX-0MX-0 prostate cancer, a PSA concentration of 60 ng/mL or lower, and WHO performance status of 0-2. A web-based application was used to randomly assign (1:1) patients to receive either standard fractionation with 39 fractions of 2 Gy in 8 weeks (five fractions per week) or hypofractionation with 19 fractions of 3·4 Gy in 6·5 weeks (three fractions per week). Randomisation was done with minimisation procedure, stratified by treatment centre and risk group. The primary endpoint is 5-year relapse-free survival. Here we report data for the acute toxicity outcomes: the cumulative incidence of grade 2 or worse acute and late genitourinary and gastrointestinal toxicity. Non-inferiority of hypofractionation was tested separately for genitourinary and gastrointestinal acute toxic effects, with a null hypothesis that cumulative incidences of each type of adverse event were not more than 8% higher in the hypofractionation group than in the standard fractionation group. We scored acute genitourinary and gastrointestinal toxic effects according to RTOG-EORTC criteria from both case report forms and patients' self-assessment questionnaires, at baseline, twice during radiotherapy, and 3 months after completion of radiotherapy. Analyses were done in the intention-to-treat population. Patient recruitment has been completed. This study is registered with www.controlled-trials.com, number ISRCTN85138529. FINDINGS Between March 19, 2007, and Dec 3, 2010, 820 patients were randomly assigned to treatment with standard fractionation (n=410) or hypofractionation (n=410). 3 months after radiotherapy, 73 (22%) patients in the standard fractionation group and 75 (23%) patients in the hypofractionation group reported grade 2 or worse genitourinary toxicity; grade 2 or worse gastrointestinal toxicity was noted in 43 (13%) patients in the standard fractionation group and in 42 (13%) in the hypofractionation group. Grade 4 acute genitourinary toxicity was reported for two patients, one (<1%) in each group. No grade 4 acute gastrointestinal toxicities were observed. We noted no significant difference in cumulative incidence by 120 days after radiotherapy of grade 2 or worse acute genitourinary toxicity (57·8% [95% CI 52·9-62·7] in the standard fractionation group vs 60·5% (55·8-65·3) in the hypofractionation group; difference 2·7%, 90% CI -2·99 to 8·48; odds ratio [OR] 1·12, 95% CI 0·84-1·49; p=0·43). The cumulative incidence of grade 2 or worse acute gastrointestinal toxicity by 120 days after radiotherapy was higher in patients given hypofractionation (31·2% [95% CI 26·6-35·8] in the standard fractionation group vs 42·0% [37·2-46·9] in the hypofractionation group; difference 10·8%, 90% CI 5·25-16·43; OR 1·6; p=0·0015; non-inferiority not confirmed). INTERPRETATION Hypofractionated radiotherapy was not non-inferior to standard fractionated radiotherapy in terms of acute genitourinary and gastrointestinal toxicity for men with intermediate-risk and high-risk prostate cancer. In fact, the cumulative incidence of grade 2 or worse acute gastrointestinal toxicity was significantly higher in patients given hypofractionation than in those given standard fractionated radiotherapy. Patients remain in follow-up for efficacy endpoints. FUNDING The Dutch Cancer Society.
Collapse
Affiliation(s)
- Shafak Aluwini
- Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
| | - Floris Pos
- Department of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Erik Schimmel
- Institute for Radiation Oncology Arnhem, Netherlands
| | - Emile van Lin
- Department of Radiation Oncology, University Medical Centre Nijmegen, Nijmegen, Netherlands
| | - Stijn Krol
- Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands
| | | | | | - Maarten Dirkx
- Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
| | | | - Ben Heijmen
- Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
| | - Luca Incrocci
- Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
| |
Collapse
|
4
|
Tree A, Alexander E, Van As N, Dearnaley D, Khoo V. Biological Dose Escalation and Hypofractionation: What is There to be Gained and How Will it Best be Done? Clin Oncol (R Coll Radiol) 2013; 25:483-98. [DOI: 10.1016/j.clon.2013.05.003] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 05/09/2013] [Indexed: 12/12/2022]
|
5
|
Hypofractionated external-beam radiotherapy for prostate cancer. Prostate Cancer 2013; 2013:103547. [PMID: 23533777 PMCID: PMC3606774 DOI: 10.1155/2013/103547] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2012] [Accepted: 10/13/2012] [Indexed: 01/19/2023] Open
Abstract
There are radiobiological rationales supporting hypofractionated radiotherapy for prostate cancer. The recent advancements in treatment planning and delivery allow sophisticated radiation treatments to take advantage of the differences in radiobiology of prostate cancer and the surrounding normal tissues. The preliminary results from clinical studies indicate that abbreviated fractionation programs can result in successful treatment of localized prostate cancer without escalation of late toxicity.
Collapse
|
6
|
Oliveira SM, Teixeira NJ, Fernandes L. What do we know about the α/β for prostate cancer? Med Phys 2012; 39:3189-201. [DOI: 10.1118/1.4712224] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
7
|
Shaffer R, Pickles T, Lee R, Moiseenko V. Deriving Prostate Alpha-Beta Ratio Using Carefully Matched Groups, Long Follow-Up and the Phoenix Definition of Biochemical Failure. Int J Radiat Oncol Biol Phys 2011; 79:1029-36. [DOI: 10.1016/j.ijrobp.2009.12.058] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2009] [Revised: 12/14/2009] [Accepted: 12/14/2009] [Indexed: 12/01/2022]
|
8
|
Fowler JF. 21 years of biologically effective dose. Br J Radiol 2010; 83:554-68. [PMID: 20603408 PMCID: PMC3473681 DOI: 10.1259/bjr/31372149] [Citation(s) in RCA: 406] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2010] [Revised: 03/15/2010] [Accepted: 03/23/2010] [Indexed: 12/25/2022] Open
Abstract
In 1989 the British Journal of Radiology published a review proposing the term biologically effective dose (BED), based on linear quadratic cell survival in radiobiology. It aimed to indicate quantitatively the biological effect of any radiotherapy treatment, taking account of changes in dose-per-fraction or dose rate, total dose and (the new factor) overall time. How has it done so far? Acceptable clinical results have been generally reported using BED, and it is in increasing use, although sometimes mistaken for "biologically equivalent dose", from which it differs by large factors, as explained here. The continuously bending nature of the linear quadratic curve has been questioned but BED has worked well for comparing treatments in many modalities, including some with large fractions. Two important improvements occurred in the BED formula. First, in 1999, high linear energy transfer (LET) radiation was included; second, in 2003, when time parameters for acute mucosal tolerance were proposed, optimum overall times could then be "triangulated" to optimise tumour BED and cell kill. This occurs only when both early and late BEDs meet their full constraints simultaneously. New methods of dose delivery (intensity modulated radiation therapy, stereotactic body radiation therapy, protons, tomotherapy, rapid arc and cyberknife) use a few large fractions and obviously oppose well-known fractionation schedules. Careful biological modelling is required to balance the differing trends of fraction size and local dose gradient, as explained in the discussion "How Fractionation Really Works". BED is now used for dose escalation studies, radiochemotherapy, brachytherapy, high-LET particle beams, radionuclide-targeted therapy, and for quantifying any treatments using ionising radiation.
Collapse
Affiliation(s)
- J F Fowler
- University of Wisconsin Medical School, Madison, WI 53792, USA.
| |
Collapse
|
9
|
Buyyounouski MK, Price RA, Harris EER, Miller R, Tomé W, Schefter T, Parsai EI, Konski AA, Wallner PE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010; 76:1297-304. [PMID: 20338473 DOI: 10.1016/j.ijrobp.2009.09.078] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2009] [Accepted: 09/08/2009] [Indexed: 12/30/2022]
Affiliation(s)
- Mark K Buyyounouski
- Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients. Radiother Oncol 2009; 92:62-7. [DOI: 10.1016/j.radonc.2009.02.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2008] [Revised: 02/02/2009] [Accepted: 02/03/2009] [Indexed: 11/17/2022]
|
11
|
Strigari L, Orlandini LC, Andriani I, d'Angelo A, Stefanacci M, Di Nallo AM, Benassi M. A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment. Phys Med Biol 2008; 53:5045-59. [DOI: 10.1088/0031-9155/53/18/013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
12
|
Daşu A. Is the α/β Value for Prostate Tumours Low Enough to be Safely Used in Clinical Trials? Clin Oncol (R Coll Radiol) 2007; 19:289-301. [PMID: 17517328 DOI: 10.1016/j.clon.2007.02.007] [Citation(s) in RCA: 123] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2006] [Revised: 01/22/2007] [Accepted: 02/05/2007] [Indexed: 12/30/2022]
Abstract
There has been an intense debate over the past several years on the relevant alpha/beta value that could be used to describe the fractionation response of prostate tumours. Previously it has been assumed that prostate tumours have high alpha/beta values, similar to most other tumours and the early reacting normal tissues. However, the proliferation behaviour of the prostate tumours is more like that of the late reacting tissues, with slow doubling times and low alpha/beta values. The analyses of clinical results carried out in the past few years have indeed suggested that the alpha/beta value that characterises the fractionation response of the prostate is low, possibly even below the 3 Gy commonly assumed for most late complications, and hence that hypofractionation of the radiation treatment might improve the therapeutic ratio (better control at the same or lower complication rate). However, hypofractionation might also increase the complication rates in the surrounding late responding tissues and if their alpha/beta value is not larger that of prostate tumours it could even lead to a decrease in the therapeutic ratio. Therefore, the important question is whether the alpha/beta value for the prostate is lower than the alpha/beta values of the surrounding late responding tissues at risk. This paper reviews the clinical and experimental data regarding the radiobiological differential that might exist between prostate tumours and the late normal tissues around them. Several prospective hypofractionated trials that have been initiated recently in order to determine the alpha/beta value or the range of values that describe the fractionation response of prostate tumours are also reviewed. In spite of several confounding factors that interfere with the derivation of a precise value, it seems that most data support a trend towards lower alpha/beta values for prostate tumours than for rectum or bladder.
Collapse
Affiliation(s)
- A Daşu
- Department of Radiation Physics, Norrland University Hospital, 901 85 Umeå, Sweden.
| |
Collapse
|
13
|
Wang JZ, Mayr NA, Nag S, Montebello J, Gupta N, Samsami N, Kanellitsas C. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapya). Med Phys 2006; 33:1025-32. [PMID: 16696479 DOI: 10.1118/1.2181294] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Many factors influence response in low-dose-rate (LDR) brachytherapy of prostate cancer. Among them, edema, relative biological effectiveness (RBE), and dose heterogeneity have not been fully modeled previously. In this work, the generalized linear-quadratic (LQ) model, extended to account for the effects of edema, RBE, and dose heterogeneity, was used to assess these factors and their combination effect. Published clinical data have shown that prostate edema after seed implant has a magnitude (ratio of post- to preimplant volume) of 1.3-2.0 and resolves exponentially with a half-life of 4-25 days over the duration of the implant dose delivery. Based on these parameters and a representative dose-volume histogram (DVH), we investigated the influence of edema on the implant dose distribution. The LQ parameters (alpha=0.15 Gy(-1) and alpha/beta=3.1 Gy) determined in earlier studies were used to calculate the equivalent uniform dose in 2 Gy fractions (EUD2) with respect to three effects: edema, RBE, and dose heterogeneity for 125I and 103Pd implants. The EUD2 analysis shows a negative effect of edema and dose heterogeneity on tumor cell killing because the prostate edema degrades the dose coverage to tumor target. For the representative DVH, the V100 (volume covered by 100% of prescription dose) decreases from 93% to 91% and 86%, and the D90 (dose covering 90% of target volume) decrease from 107% to 102% and 94% of prescription dose for 125I and 103Pd implants, respectively. Conversely, the RBE effect of LDR brachytherapy [versus external-beam radiotherapy (EBRT) and high-dose-rate (HDR) brachytherapy] enhances dose effect on tumor cell kill. In order to balance the negative effects of edema and dose heterogeneity, the RBE of prostate brachytherapy was determined to be approximately 1.2-1.4 for 125I and 1.3-1.6 for 103Pd implants. These RBE values are consistent with the RBE data published in the literature. These results may explain why in earlier modeling studies, when the effects of edema, dose heterogeneity, and RBE were all ignored simultaneously, prostate LDR brachytherapy was reported to show an overall similar dose effect as EBRT and HDR brachytherapy, which are independent of edema and RBE effects and have a better dose coverage.
Collapse
Affiliation(s)
- Jian Z Wang
- Department of Radiation Medicine, The Ohio State University, Columbus, Ohio 43210, USA.
| | | | | | | | | | | | | |
Collapse
|
14
|
Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004; 60:1013-5. [PMID: 15519768 DOI: 10.1016/j.ijrobp.2004.04.014] [Citation(s) in RCA: 142] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2004] [Accepted: 04/02/2004] [Indexed: 12/12/2022]
|
15
|
Carlone M, Wilkins D, Nyiri B, Raaphorst P. TCP isoeffect analysis using a heterogeneous distribution of radiosensitivity. Med Phys 2004; 31:1176-82. [PMID: 15191307 DOI: 10.1118/1.1711415] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A formula for the alpha/beta ratio is derived using the heterogeneous (population averaged) tumor control model. This formula is nearly identical to the formula obtained using the homogeneous (individual) tumor control model, but the new formula includes extra terms showing that the alpha/beta ratio, the ratio of the mean value of a divided by the mean value of beta that would be observed in a patient population, explicitly depends on the survival level and heterogeneity. The magnitude of this correction is estimated for prostate cancer, and this appears to raise the mean value of the ratio estimate by about 20%. The method also allows investigation of confidence limits for alpha/beta based on a population distribution of radiosensitivity. For a widely heterogeneous population, the upper 95% confidence interval for the alpha/beta ratio can be as high as 7.3 Gy, even though the population mean is between 2.3 and 2.6 Gy.
Collapse
Affiliation(s)
- Marco Carlone
- Department of Physics, Carleton University, Ottawa K1S 5B6, Canada
| | | | | | | |
Collapse
|
16
|
Brenner DJ. Hypofractionation for prostate cancer radiotherapy--what are the issues? Int J Radiat Oncol Biol Phys 2003; 57:912-4. [PMID: 14575821 DOI: 10.1016/s0360-3016(03)01456-1] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Abstract
PURPOSE Recently, low alpha/beta values of 1.2 and 1.5 Gy for prostate tumors have been derived from clinical results of external beam radiotherapy and of permanent implants of (125)I and (103)Pd. In the analyses the contributions of tumor repopulation, and edema as a result of inserting radioactive seeds in the prostate, have been ignored. In this paper we reanalyzed the clinical data and introduced the contribution of repopulation and edema. METHODS AND MATERIALS The linear quadratic-biologically effective dose model was used for reanalysis. In this model, the influence of repopulation and edema has been taken into account. The biologically effective dose was calculated as a function of alpha/beta for 2 brachytherapy regimens with (125)I and (103)Pd and 2 fractionated treatments, and for different half-times for repair of sublethal damage for the brachytherapy regimens. RESULTS We have found a plausible alpha/beta value of 3.1 to 3.9 Gy, an alpha value of 0.1 to 0.15 Gy(-1), and a half-time of repair of about 0.5 h. CONCLUSIONS It seems now that the alpha/beta value is low, 3.1-3.9 Gy, but not as low as the 1.2 and 1.5 Gy reported earlier.
Collapse
Affiliation(s)
- Henk B Kal
- Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands.
| | | |
Collapse
|
18
|
Wang JZ, Li XA, Yu CX, DiBiase SJ. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys 2003; 57:1101-8. [PMID: 14575842 DOI: 10.1016/s0360-3016(03)00747-8] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE Accumulating evidence demonstrates that prostate cancer has a low alpha/beta ratio. However, several challenging issues have been raised from previous studies, including the biologic equivalence between external beam radiotherapy (EBRT) and brachytherapy, the effect of relative biologic effectiveness (RBE) for permanent implantation, and the systematic uncertainties of multi-institutional and multi-modality clinical data. The purpose of this study is to address these issues by reexamining a reported clinical outcome of high-dose-rate (HDR) brachytherapy and to confirm the low alpha/beta ratio for prostate cancer. METHODS AND MATERIALS The generalized linear-quadratic (LQ) model with considerations of sublethal damage repair and clonogen repopulation was used to calculate the cell-killing efficiency of radiotherapy treatments for prostate cancer. Standard models of tumor cure based on Poisson statistics were used to bridge cell killing to treatment outcome. The data collected in a clinical trial using EBRT plus HDR brachytherapy boost for prostate cancer at William Beaumont Hospital (WBH) were reanalyzed. A 4-year post-treatment time endpoint was chosen as compared to the 3-year endpoint used in the previous study because of better maturity and stability of the data. The least chi-square method was employed to fit the clinical data to estimate the LQ parameters as well as their confidence intervals. The number of clonogens for prostate tumors derived in a separate study was used as a constraint for the data modeling to improve the confidence level. RESULTS Our analysis demonstrates that only relationships among the LQ parameters, not their definitive and unique values, can be derived from the WBH data set alone. This is due to the large statistical uncertainties, i.e., the small numbers of sampled patients. By combining with the results obtained with the clinical data from Memorial Sloan-Kettering Cancer Center (MSKCC), a new set of LQ parameters (alpha = 0.14 +/- 0.05 Gy(-1), alpha/beta = 3.1(-1.6)(+2.6) Gy) was obtained from the current analysis of the WBH data without dealing with data from permanent implants. The results are consistent with a previous study based on the biologic equivalence between EBRT and permanent implants with a consideration of tumor repopulation. This set of LQ parameters provides a consistent interpretation of clinical data currently available for prostate cancer. CONCLUSIONS This study provides further evidence to support that prostate cancer has a low alpha/beta ratio of about 3.1 Gy. This study shows that the RBE effect in permanent implantation may not be clinically significant for prostate cancer. The consistency found between this analysis and the previous reported study supports the general biologic equivalence between EBRT and brachytherapy treatments for prostate cancer. The low alpha/beta ratio opens the door to search for more effective radiotherapeutic approaches for prostate cancer, e.g., hypofractionation radiotherapy.
Collapse
Affiliation(s)
- Jian Z Wang
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201-1595, USA
| | | | | | | |
Collapse
|
19
|
Craig T, Moiseenko V, Battista J, Van Dyk J. The impact of geometric uncertainty on hypofractionated external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2003; 57:833-42. [PMID: 14529791 DOI: 10.1016/s0360-3016(03)00638-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PURPOSE Recent publications indicate alpha/beta for prostate carcinoma could be lower than assumed. Therefore, hypofractionation might increase the therapeutic ratio. However, patient repositioning and organ motion may affect hypofractionated treatments more than conventional treatments. Our purpose is to evaluate the potential impact of geometric uncertainties on hypofractionated treatments. METHODS AND MATERIALS Tumor control probability (TCP) and normal tissue complication probability (NTCP) are calculated for simulated conventional and hypofractionated treatments, assuming alpha/beta of 1.5 Gy for prostate and 3.0 Gy for rectum. A Monte Carlo simulation randomly samples systematic and random displacements and produces the cumulative dose distribution for the prostate and rectum. The limiting number of fractions and the impact of different alpha/beta values are also explored. RESULTS A consistent but small reduction in TCP is seen with hypofractionation (generally <1%) as a result of geometric uncertainties. Escalated hypofractionation seems to allow large TCP gains ( approximately 20%) without increasing NTCP. Treatments of five fractions seem to affect outcome minimally. The alpha/beta value has a much greater impact on TCP than geometric uncertainties. CONCLUSION The potential increased influence of geometric uncertainties on hypofractionation seems small. Limited knowledge of radiobiologic response is likely a greater obstacle to prostate hypofractionation than geometric uncertainties.
Collapse
Affiliation(s)
- Tim Craig
- Radiation Oncology Program, London Regional Cancer Centre, London, Ontario, Canada
| | | | | | | |
Collapse
|
20
|
Fowler JF, Ritter MA, Fenwick JD, Chappell RJ. How low is the alpha/beta ratio for prostate cancer? In regard to Wang et al., IJROBP 2003;55:194-203. Int J Radiat Oncol Biol Phys 2003; 57:593-5; author reply 595-6. [PMID: 12957275 DOI: 10.1016/s0360-3016(03)00364-x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Carlone M, Wilkins D, Nyiri B, Raaphorst P. Comparison of α/β estimates from homogeneous (individual) and heterogeneous (population) tumor control models for early stage prostate cancer. Med Phys 2003; 30:2832-48. [PMID: 14596319 DOI: 10.1118/1.1612946] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Radiobiological parameter estimates for prostate cancer are obtained from both a homogeneous (individual) and heterogeneous (population) tumor control model based on Poisson statistics and the linear quadratic model of cell survival. Parameter estimates for both models are highly correlated: statistically equivalent fits are achievable using either (1) linear quadratic (LQ) parameters with low numbers of radioresistant tumor stem cells, or (2) LQ parameters with corresponding larger number of radiosensitive tumor stem cells. A theoretical framework is developed to explain this correlation. A Monte Carlo error analysis based on binomial statistics is used to estimate confidence intervals for all parameter estimates. It was found that both the homogeneous and heterogeneous models produce approximately equivalent estimates of radiobiological parameters, including the alpha/beta ratio. However, the 95% confidence interval for the alpha/beta ratio derived from the heterogeneous model are considerably larger than those derived from the homogeneous model, which indicate the homogeneous model overestimates the statistical significance of the alpha/beta estimate.
Collapse
Affiliation(s)
- Marco Carlone
- Department of Physics, Carleton University, Ottawa K1S 5B6, Canada
| | | | | | | |
Collapse
|
22
|
Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 56:1093-104. [PMID: 12829147 DOI: 10.1016/s0360-3016(03)00132-9] [Citation(s) in RCA: 236] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
PURPOSE Recent analyses of clinical results have suggested that the fractionation sensitivity of prostate tumors is remarkably high; corresponding point estimates of the alpha/beta ratio for prostate cancer are around 1.5 Gy, much lower than the typical value of 10 Gy for many other tumors. This low alpha/beta value is comparable to, and possibly even lower than, that of the surrounding late-responding normal tissue in rectal mucosa (alpha/beta nominally 3 Gy, but also likely to be in the 4-5 Gy range). This lower alpha/beta ratio for prostate cancer than for the surrounding late-responding normal tissue creates the potential for therapeutic gain. We analyze here possible high-gain/low-risk hypofractionated protocols for prostate cancer to test this suggestion. METHODS AND MATERIALS Using standard linear-quadratic (LQ) modeling, a set of hypofractionated protocols can be designed in which a series of dose steps is given, each step of which keeps the late complications constant in rectal tissues. This is done by adjusting the dose per fraction and total dose to maintain a constant level of late effects. The effect on tumor control is then investigated. The resulting estimates are theoretical, although based on the best current modeling with alpha/beta parameters, which are discussed thoroughly. RESULTS If the alpha/beta value for prostate is less than that for the surrounding late-responding normal tissue, the clinical gains can be rather large. Appropriately designed schedules using around ten large fractions can result in absolute increases of 15% to 20% in biochemical control with no evidence of disease (bNED), with no increase in late sequelae. Early sequelae are predicted to be decreased, provided that overall times are not shortened drastically because of a possible risk of acute or consequential late reactions in the rectum. An overall time not shorter than 5 weeks appears advisable for the hypofractionation schedules considered, pending further clinical trial results. Even if the prostate tumor alpha/beta ratio turns out to be the same (or even slightly larger than) the surrounding late-responding normal tissue, these hypofractionated regimens are estimated to be very unlikely to result in significantly increased late effects. CONCLUSIONS The hypofractionated regimens that we suggest be tested for prostate-cancer radiotherapy show high potential therapeutic gain as well as economic and logistic advantages. They appear to have little potential risk as long as excessively short overall times (<5 weeks) and very small fraction numbers (<5) are avoided. The values of bNED and rectal complications presented are entirely theoretical, being related by LQ modeling to existing clinical data for approximately intermediate-risk prostate cancer patients as discussed in detail.
Collapse
Affiliation(s)
- Jack F Fowler
- Department of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA.
| | | | | | | |
Collapse
|
23
|
Lindsay PE, Moiseenko VV, Van Dyk J, Battista JJ. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer. Phys Med Biol 2003; 48:507-22. [PMID: 12630745 DOI: 10.1088/0031-9155/48/4/307] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The sensitivity of estimates of alpha/beta for prostate tumours to dose heterogeneity in 125I brachytherapy implants, as well as to variation in selected radiobiological parameters, is analysed. The tumour control probabilities of brachytherapy and external beam radiotherapy are equated for ranges of alpha, Tpot, RBE and external beam dose. For each combination of parameters, the equality is used to derive the value of alpha/beta. Different clinical (non-uniform) brachytherapy dose distributions, and three uniform brachytherapy dose distributions (120, 144 and 160 Gy) are used. For 'nominal' input parameter values of Tpot = 45 days, alpha = 0.2 Gy(-1), RBE = 1.4, and an external beam dose of 70 Gy, the values obtained for alpha/beta ranged between 2.1 and 12.3 Gy for all of the clinical DVHs, between 2.1 and 3.8 Gy for the better quality clinical implants and between 1.0 and 1.8 Gy for the uniform brachytherapy doses. When only 2% of the volume receiving the lowest dose is omitted from the clinical DVHs, the estimated alpha/beta values ranged between 1.4 and 2.1 Gy. When ranges of input parameters were also considered, the overall range of alpha/beta values for the clinical brachytherapy dose distributions lay between 1.1 and 12.3 Gy for the three best clinical implants, and between 0.7 and 6.3 Gy for uniform doses. We conclude that estimation of alpha/beta without taking into account dose heterogeneity and inter-patient variation may underestimate the actual value alpha/beta.
Collapse
Affiliation(s)
- P E Lindsay
- Radiation Oncology Program, London Regional Cancer Centre, 790 Commissioners Rd E, London, Ontario, Canada, N6A-4L6.
| | | | | | | |
Collapse
|